Drug intelligence / Profile preview

B2065

Development stage: Phase 2
Lead developer: Tasly Pharmaceutical
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

B2065 is an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) therapy developed by Tasly Pharmaceutical Group for the treatment of acute ischemic stroke. As a cell-based therapeutic, B2065 is designed to be administered via intravenous infusion within a critical 36-hour window following the onset of stroke symptoms. The therapy aims to leverage the immunomodulatory and neuroprotective properties of mesenchymal stromal cells to mitigate secondary brain injury, reduce neuroinflammation, and promote neuroregeneration and functional recovery. It is currently being evaluated in Phase I/IIa clinical trials to assess its safety, tolerability, and preliminary efficacy in stroke patients.

Other names: allogeneic adipose-derived mesenchymal stromal cellsAD-MSC injection

Beyond the preview

Go deeper on B2065.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B2065.

Explore the full profile